Impact on the composition of the faecal flora by a new probiotic preparation: Preliminary data on maintenance treatment of patients with ulcerative colitis

Alimentary Pharmacology and Therapeutics

Volumn 13, Issue 8, 1999, Pages 1103-1108

  Venturi, A ^b   Gionchetti, P ^b   Rizzello, F ^b   Johansson, R ^b   Zucconi, E ^b   Brigidi, P ^b   Matteuzzi, D ^b   Campieri, M ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PROBIOTIC AGENT; UNCLASSIFIED DRUG; VSL 3;

ADULT; ANAEROBIC BACTERIUM; ANGIONEUROTIC EDEMA; ARTICLE; BACTEROIDES; CLINICAL ARTICLE; CLINICAL TRIAL; CLOSTRIDIUM; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; ENDOSCOPY; ENTEROCOCCUS; FECES CULTURE; FECES MICROFLORA; FEMALE; HUMAN; INTESTINE FLORA; LACTOBACILLUS; LACTOBACILLUS BIFIDUS; MAINTENANCE THERAPY; MALE; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REMISSION; STREPTOCOCCUS SALIVARIUS; STREPTOCOCCUS THERMOPHILUS; ULCERATIVE COLITIS; URTICARIA; VOMITING;

ADULT; AGED; BIFIDOBACTERIUM; COLITIS, ULCERATIVE; FECES; FEMALE; HUMANS; HYDROGEN-ION CONCENTRATION; LACTOBACILLUS; MALE; MESALAMINE; MIDDLE AGED; PROBIOTICS; RECURRENCE; STREPTOCOCCUS;

EID: 0032815979     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.1999.00560.x     Document Type: Article

References (28)

1. 1 Dissanayake AS, Truelove SC. A controlled therapeutic trial of sulphasalazine. Gut 1973; 14: 93-6.
2. 2 Das KM, Eastwood MA, Mc Manus JPA, Sircus W. Adverse reaction during salicylazosulphapyridine therapy and the relation with drug metabolism and acetylator phenotype. N Engl J Med 1973; 289: 491-5.
3. 3 Campieri M, Gionchetti P. The use of salicylates in patients with inflammatory bowel disease. Clinical Challenges in Inflammatory Bowel Disease, Diagnosis Prognosis and Treatment. Falk Symposium. Lancaster, UK: Kluwer Academic Publishers, 1997: 141-5.
4. 4 Sutherland LR, May GR, Shaffer EA. Sulphasalazine revisited: a meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis. Ann Intern: Med 1993; 118: 540-9.
5. 5 Sartor RB. Pathogenesis and immune mechanisms of chronic inflammatory bowel Disease. Am J Gastroenterol 1997; 2: 5S-11S.
6. 6 Fuller R. Probiotics in human medicine. Gut 1991; 32: 439-42.
7. 7 Mao Y, Nobaek S, Kasravi B, et al. The effects of Lactobacillus strains and oat fibre on methotrexate-induced Enterocolitis in rats. Gastroenterology 1996; 111: 334-44.
8. 8 Fabia R, Ar'Rajab A, Johansson ML, et al. Impairment of bacterial flora in human ulcerative colitis and experimental colitis in the rat. Digestion 1993; 54: 248-55.
9. 9 Madsen KL, Tavrini MM, Doyle JSG, et al. Lactobacillus sp prevents developments of enterocolitis in interleukin-10 gene deficient mice. Gastroenterology 1997; 112: A 1030 (Abstract).
10. 10 Schultz M, Veltkamp C, Dielman LA, Wyrick PB, Tonkonogy SL, Sartor RB. Continuous feeding of lactobacillus plantarum attenuates estabilished colitis in interleukin-10 deficient mice Gastroenterology 1998; 114: 4; G4426 (Abstract).
11. 11 Kruis W, Schuts E, Fric P, Fixa B, Judmaier G, Stolte M. Double-blind comparison of an oral Escherichia Coli preparation and Mesalazina in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 1997; 11: 853-8.
12. 12 Rembacken BJ, Snelling AM, Hawkey PM, Dixon ATR. A double blind trial of non pathogenic IX. coli vs mesalazine for the treatment of ulcerative colits. Gut 1997; 41(Suppl. 3): 3911.
13. 13 Baron JH, Connel AM, Lennard-Jones JE. Variation between observers in describing mucosal appearances in proctocolitis. Br Med J 1964; 1: 89-92.
14. 14 Truelove SC, Richard WCD. Biopsy studies in ulcerative colitis Br Med J 1956; 1: 1315-8.
15. 15 Summanen P, Baron EJ, et al., eds. Wadsworth Anaerobic Bacteriology Manual, Fifth Edition. Singapore: STAR Publishers Co, 1993.
16. 16 Biavati B, Sgorbati B, Scardovi V. The genus Bifidobacterium. In: Balows A, Tripes HG, Dworkin W, Harder W, Schleifer KH, eds. The Prokariotes Handbook on the Biology of the Bacteria. Berlin: Springer-Verlag, 1992: 816-33.
17. 17 Bengmark S. Ecological control of the gastrointestinal tract. The role of probiotic flora. Gut 1998; 42: 2-7.
18. 18 Fernandes CF, Shahami KM, Amer MA. Therapeutic role of dietary lactobacilli and lactobacilli fermented dairy products. FEMS Microbiolol Rev 1987; 46: 343-56.
19. 19 Salminen S, Deighton M, Gorbach S. Lactic acid bacteria in health and disease In:von : Salminen S, Wright A, eds. Lactic Acid Bacteria. New York: Dekker, 1993: 199-225.
20. 20 Ahn C, Stiles ME. Antibacterial activity of lactic acid bacteria isolated from vacuum-packed meats. J Appl Bacteriol 1990; 69: 302-10.
21. 21 Malin M, Suomalainen H, Saxelin M, Isolauri E. Promotion of IgA immune response in patients with Crohn's disease by oral Bacteriotherapy with Lactabacillus GG. Ann Nutr Metab 1996; 40: 137-45.
22. 22 Axelsson LT, Chung TC, Dobrogosz WJ, Lindgreen SE. Production of a broad spectrum antimicrobial substance by Lactobacillus reuteri. Microb Ecol Health Dis 1989; 2: 131-6.
23. 23 Gorbach SL. Lactic acid bacteria and human health. Ann Med 1990; 22: 37-41.
24. 24 McDonought FE, Wells P, Wong NP, Hitchins AD, Bodwell CE. Role of vitamins and mineral in growth stimulation of rats fed yogurt. Fed Proc 1983; 42: 556.
25. 25 Gionchetti P, Rizzello F, Venturi A, et al. Maintenance treatment of chronic pouchitis: a randomised placebo-controlled trial with a new probiotic preparation. Gastroenterology 1998; 114: 4; G4037.
26. 26 Lee YK, Salminen S. The coming of age of probiotics. Trends Food Sci Technol 1995; 6: 241-5.
27. 27 Bengmark S. Econutrition and health maintenance - a new concept to prevent GI inflammation ulceration and sepsis. Clin Nutrition 1996; 15: 1-10.
28. 28 Berg RD. Probiotic, prebiotic or 'combiotics'? Trends Microbiol 1998; 6: 89-92.